Status: Not yet recruiting
Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma
This study will determine the safety and tolerability of RVU120 as a single agent and in combination with the mTOR inhibitor everolimus in children with recurrent or progressive G3 or G4 medulloblastoma and provide preliminary data regarding the efficacy of this treatment approach.
Participants needed: 48
Trial details
Phase: Phase 1Age: 3-18Biological sex: AllType: InterventionalSponsor: Bożenna Dembowska BagińskaUpdated: Oct 8, 2026Locations: 1
Eligibility criteria
Diagnosis: Recurrent/progressive Group 3 or Group 4 medulloblastoma confirmed by... [+9]
Pregnancy/lactation - Pregnant or lactating patients. Negative serum pregnancy t... [+6]